Cuu Long Pharmaceutical JSC (HOSE: DCL)
Vietnam
· Delayed Price · Currency is VND
25,750
0.00 (0.00%)
At close: Oct 3, 2024
DCL Income Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jan '21 Jan 1, 2021 | Jan '20 Jan 1, 2020 | 2019 - 2015 |
Revenue | 1,209,319 | 1,143,946 | 1,015,686 | 703,634 | 671,246 | 752,014 | Upgrade
|
Revenue Growth (YoY) | 11.47% | 12.63% | 44.35% | 4.83% | -10.74% | -6.49% | Upgrade
|
Cost of Revenue | 989,376 | 934,032 | 733,585 | 493,482 | 483,609 | 564,820 | Upgrade
|
Gross Profit | 219,943 | 209,914 | 282,100 | 210,152 | 187,637 | 187,194 | Upgrade
|
Selling, General & Admin | 147,207 | 139,188 | 153,815 | 123,371 | 139,733 | 174,407 | Upgrade
|
Operating Expenses | 147,207 | 139,188 | 153,815 | 123,371 | 139,733 | 174,407 | Upgrade
|
Operating Income | 72,736 | 70,726 | 128,285 | 86,781 | 47,904 | 12,788 | Upgrade
|
Interest Expense | -29,160 | -30,530 | -39,627 | -36,264 | -33,264 | -37,582 | Upgrade
|
Interest & Investment Income | 36,841 | 39,667 | 52,712 | 51,929 | 71,400 | 135,391 | Upgrade
|
Currency Exchange Gain (Loss) | -1,539 | -2,705 | 77.03 | -90.68 | 468.88 | 1,088 | Upgrade
|
Other Non Operating Income (Expenses) | 1,064 | 953.02 | 94.19 | 6,058 | -564.86 | -6,952 | Upgrade
|
EBT Excluding Unusual Items | 79,942 | 78,111 | 141,542 | 108,412 | 85,944 | 104,733 | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | 1,872 | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | -370.64 | - | - | - | - | - | Upgrade
|
Pretax Income | 79,571 | 78,111 | 141,542 | 110,284 | 85,944 | 104,733 | Upgrade
|
Income Tax Expense | 16,425 | 15,976 | 28,628 | 22,528 | 17,017 | 17,729 | Upgrade
|
Earnings From Continuing Operations | 63,146 | 62,134 | 112,914 | 87,756 | 68,928 | 87,004 | Upgrade
|
Minority Interest in Earnings | -494.96 | -416.96 | -1,273 | -1,796 | -2,537 | 1,470 | Upgrade
|
Net Income | 62,651 | 61,717 | 111,641 | 85,961 | 66,391 | 88,474 | Upgrade
|
Preferred Dividends & Other Adjustments | -1,000 | - | 3,000 | 2,000 | 2,110 | 2,110 | Upgrade
|
Net Income to Common | 63,651 | 61,717 | 108,641 | 83,961 | 64,281 | 86,364 | Upgrade
|
Net Income Growth | -40.50% | -44.72% | 29.87% | 29.48% | -24.96% | 605.84% | Upgrade
|
Shares Outstanding (Basic) | 73 | 73 | 70 | 57 | 57 | 57 | Upgrade
|
Shares Outstanding (Diluted) | 73 | 73 | 70 | 57 | 57 | 75 | Upgrade
|
Shares Change (YoY) | -0.05% | 4.11% | 22.02% | 1.17% | -24.64% | 32.70% | Upgrade
|
EPS (Basic) | 871.45 | 844.97 | 1548.46 | 1460.20 | 1131.05 | 1519.61 | Upgrade
|
EPS (Diluted) | 871.45 | 844.97 | 1548.00 | 1460.00 | 1131.00 | 1228.53 | Upgrade
|
EPS Growth | -38.92% | -45.42% | 6.03% | 29.09% | -7.94% | 466.06% | Upgrade
|
Free Cash Flow | -173,415 | -200,343 | -683,099 | -123,174 | -8,582 | 65,060 | Upgrade
|
Free Cash Flow Per Share | -2374.21 | -2742.89 | -9736.25 | -2142.18 | -151.01 | 862.67 | Upgrade
|
Gross Margin | 18.19% | 18.35% | 27.77% | 29.87% | 27.95% | 24.89% | Upgrade
|
Operating Margin | 6.01% | 6.18% | 12.63% | 12.33% | 7.14% | 1.70% | Upgrade
|
Profit Margin | 5.26% | 5.40% | 10.70% | 11.93% | 9.58% | 11.48% | Upgrade
|
Free Cash Flow Margin | -14.34% | -17.51% | -67.26% | -17.51% | -1.28% | 8.65% | Upgrade
|
EBITDA | 110,721 | 108,737 | 166,420 | 121,054 | 76,184 | 52,405 | Upgrade
|
EBITDA Margin | 9.16% | 9.51% | 16.38% | 17.20% | 11.35% | 6.97% | Upgrade
|
D&A For EBITDA | 37,985 | 38,011 | 38,135 | 34,273 | 28,280 | 39,617 | Upgrade
|
EBIT | 72,736 | 70,726 | 128,285 | 86,781 | 47,904 | 12,788 | Upgrade
|
EBIT Margin | 6.01% | 6.18% | 12.63% | 12.33% | 7.14% | 1.70% | Upgrade
|
Effective Tax Rate | 20.64% | 20.45% | 20.23% | 20.43% | 19.80% | 16.93% | Upgrade
|
Revenue as Reported | 1,209,319 | 1,143,946 | 1,015,686 | 703,634 | 671,246 | 752,014 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.